BIOCRYST PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $2.65 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-02-26
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.65M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $3.12M.
- 2025-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $3.63M.
- 2025-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $4.09M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2025-12-31 | $2.65M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.12M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $3.63M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $4.09M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $3.95M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.87M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $3.65M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $4.02M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $4.32M 10-K · filed 2025-02-25 |
| 2022-12-31 | $2.56M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |